• Bukwang Pharm signed a technology licensing and exclusive supply agreement with Saudi Arabia’s NASAQ for diabetic polyneuropathy treatment Dexid on November 4, 2026.
• The initial five-year agreement renews automatically for two-year periods.
• Five-year minimum purchases total about USD 2.66 million (KRW 3.7 billion), versus projected sales of USD 4.53 million (KRW 6.3 billion).
• NASAQ will handle Saudi regulatory approval, marketing and distribution; Bukwang will support approval and supply finished products.
• The agreement includes technology transfer for local production, supporting Saudi Arabia’s Vision 2030 pharmaceutical localization policy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.